German biotech BioNTech today announced that the US Food and Drug Administration (FDA) has granted fast track designation to ...

Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 ...

Strategic collaborations with partners such as Bristol-Myers Squibb and Genentech are intended to accelerate progress. While the pipeline is broadening, management notes that none of the oncology ...

BioNTech SE (NASDAQ:BNTX) on Thursday agreed to acquire CureVac N.V. (NASDAQ:CVAC) in an all-stock transaction. According to the agreement, shareholders can exchange CureVac shares for around $5.46 in ...

BioNTech has established a diversified oncology portfolio including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, comprising ADCs and cell therapies, to ...

BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to ...

MAINZ, Germany, March 11, 2024 – BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American ...

BioNTech maintains strong cash reserves (€15.85B) despite widening losses as COVID revenues decline and R&D expenses increase. BNT327 (PD-L1/VEGF-A bispecific) advances to Phase 3 trials, but shares ...

BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and ...

BioNTech, the German biotech that partnered with Pfizer to develop the first COVID-19 vaccine to earn the FDA’s emergency use authorization, is now using mRNA to tackle another disease: malaria. The ...

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...

Filed in a Delaware federal court, the lawsuits claim the companies copied technology developed by Bayer's subsidiary, Monsanto, in the 1980s. This pioneering work, originally designed to strengthen ...